drugset / Trial / NCT01934634
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer
Phase 1
Unknown
24 enrolled
US Oncology Research
Delta Clinical Research, LLC · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this study is to identify the maximum tolerated dose and dose-limiting side effects of LCL161 in combination with gemcitabine and nab-paclitaxel and to provide safety data in patients with measurable metastatic pancreatic cancer.
Timeline
- Start
- 2014-03
- Primary completion
- 2016-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCL161 | Small molecule | 300 mg | Oral |
| Subject | LCL161 | Small molecule | 600 mg | Oral |
| Subject | LCL161 | Small molecule | 1200 mg | Oral |
| Subject | LCL161 | Small molecule | 1800 mg | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |